3 References 1. Kohtala S. Ketamine – 50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep. 2021; 73: 323–345 doi: 10.1007/s43440-021-00232-4. 2. Simons P, Olofsen E, Velzen M van, Lemmen M van, Mooren R, Dasselaar T van. S-ketamine oral thin film – Part 1: population pharmacokinetics of S-ketamine, S-norketamine and S-hydroxynorketamine. Front Pain Res. 2022; doi: 10.3389/fpain.2022.946486. 3. Kamp J, Velzen M van, Olofsen E, Boon M, Dahan A, Niesters M. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Exp Opinion Drug Metab Toxicol. 2019; 15: 1033–1041 doi: 10.1080/17425255.2019.1689958. 4. Kamp J, Jonkman K, Velzen M van, Aarts L, Niesters M, Dahan A, al. et. Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine and dehydronorketamine: a model-based analysis. Br J Anaesth. 2020; 125: 750–761 doi: 10.1016/j.bja.2020.06.067. 5. Olofsen E, Noppers I, Niesters M, Kharasch E, Aarts L, Sarton E, al. et. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology. 2012; 117: 353–364 doi: 10.1097/ALN.0b013e31825b6c91. 6. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, al. et. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016; 533: 481–486 doi: 10.1038/nature17998. 61
RkJQdWJsaXNoZXIy MTk4NDMw